Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 149-159

  Celegato, Marta ^a   Borghese, Cinzia ^a   Casagrande, Naike ^a   Carbone, Antonino ^a   Colombatti, Alfonso ^a,b   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Bortezomib; Cancer associated fibroblasts; CD44; CD49d; Hodgkin disease; IRF4; Tumor microenvironment

Indexed keywords

ALPHA4 INTEGRIN; BORTEZOMIB; CD40 LIGAND; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 4;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL VIABILITY; CLASSICAL HODGKIN LYMPHOMA; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; FIBROBLAST; GROWTH INHIBITION; HUMAN; LYMPHOMA CELL LINE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL FACTOR;

BORONIC ACIDS; CD40 LIGAND; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; INTERFERON REGULATORY FACTORS; NF-KAPPA B; PYRAZINES;

EID: 84891352190     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.800196     Document Type: Article

References (37)

1. Kuppers R. The biology of Hodgkin' s lymphoma. N at Rev Cancer 2009; 9: 15-27.
2. Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol 2010; 221: 248-263.
3. Aldinucci D, Poletto D, Nanni P, et al. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J. Haematol 2002; 118: 1055-1064.
4. Cattaruzza L, Gloghini A, Olivo K, et al. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J. Cancer 2009; 125: 1092-1101.
5. Ungefroren H, Sebens S, Seidl D, et al. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011; 9: 18.
6. Aldinucci D, Lorenzon D, Olivo K, et al. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004; 45: 1731-1739.
7. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
8. Tamura T, Tailor P, Yamaoka K, et al. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J. Immunol 2005; 174: 2573-2581.
9. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006; 7: 773-782.
10. Shaffer AL, Emre NC, Romesser PB, et al. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009; 15: 2954-2961.
11. Carbone A, Gloghini A, Aldinucci D, et al. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J. Haematol 2002; 117: 366-372.
12. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
13. Gualco G, Weiss LM, Bacchi CE. MUM1/IRF4: A review. Appl Immunohistochem Mol Morphol 2010; 18: 301-310.
14. Tiacci E, Doring C, Brune V, et al. A nalyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609-4620.
15. Aldinucci D, Gloghini A, Pinto A, et al. The role of CD40/ CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma 2012; 53: 195-201.
16. Aldinucci D, Rapana ' B, Olivo K, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J. Haematol 2010; 148: 115-118.
17. Aldinucci D, Celegato M, Borghese C, et al. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J. Haematol 2011; 152: 182-190.
18. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J. Cancer 2008; 122: 769-776.
19. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/ RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J. Cancer 2003; 107: 197-201.
20. Einsele H. Bortezomib. Recent results. Cancer Res 2010; 184: 173-187.
21. Ruschak AM, Slassi M, Kay LE, et al. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl Cancer Inst 2011; 103: 1007-1017.
22. Huang X, Di LM, Jayabalan D, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012; 120: 1095-1106.
23. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
24. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207-3215.
25. Mizuno H, Nakayama T, Miyata Y, et al. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 2012; 26: 2269-2276.
26. Vahdat AM, Reiners KS, Simhadri VL, et al. TNF-Alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia 2010; 24: 51-57.
27. Younes A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8: 85-96.
28. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993; 9: 1-25.
29. Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996; 87: 3418-3428.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships:the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
31. Cattaruzza L, Fregona D, Mongiat M, et al. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int J. Cancer 2011; 128: 206-215.
32. Spessotto P, Lacrima K, Nicolosi PA, et al. Fluorescence-based assays for in vitro analysis of cell adhesion and migration. Methods Mol Biol 2009; 522: 221-250.
33. Pivetta E, Scapolan M, Wassermann B, et al. Blood-derived human osteoclast resorption activity is impaired by hyaluronan-CD44 engagement via a p38-dependent mechanism. J. Cell Physiol 2011; 226: 769-779.
34. Kuppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J. Clin Invest 2012; 122: 3439-3447.
35. Ranuncolo SM, Pittaluga S, Evbuomwan MO, et al. Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 2012; 120: 3756-3763.
36. Fabre C, Mimura N, Bobb K, et al. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012; 18: 4669-4681.
37. Allen C, Saigal K, Nottingham L, et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 2008; 14: 4175-4185.